They bring this one out of stall as last ditch effort along with other alias'. It's a penhead production because he wrote his little pills statement with no effect. The spike wasn't fake, it is a dagger to shortie who stayed too long. Penhead just go long, now.
Downtrend broken, maybe head back to $33 soon? Set up base camp for another climb. Get some new sherpas to make the climb, my pack is full. LONG
It's just that I know that I know, amen! No need to consult the dead, soli saves, lives.
IBB is large cap, small fry like ACRX just underbrush that can grow up quickly, bigger bios buy up smaller to keep growth going.
Beavy, we have a negative nelly here, penciltechy, can you sharpen him up with your long chompers?
You can listen to earnings call replay on website. Lots of info. Revs. also come from EU zalviso, 15 million approval milestone, $65 million PDLI deal.
Let's have a debate. Longs are the candidates (Rubio, Cruz, Christie), Lurker and poo poo crew are Carlos Chimpneana, Becky Slow and Cramer chimp (drive by cheap shots). Get it now?
Pennhead sir, $20 buck may be for the govvy contracts, because they fund ARX04 quite a lot with grant money. Pam said they do a big study to determine prices for masses. I think it could go higher. I hope you see the light soon, preserve those British pounds, mate.
Beavy Pie!!! Glad to see you. I have a CEMP Lodge they drained the pond temporarily to clear some riff raff. Now fresh water for wintering down, spring will be wild with new critters taking up floats. :#3
Get a Lodge here and there if you can.
TTPH is hard, the IV will find some use, but oral maybe not per trial results that killed the pond to stagnation. Some critters trade the near term ranges.
You may want to listen to earnings CC and call on ACRX website. The company lead drug-device Zalviso was up for US PDUFA in July 2014. The drug trials showed efficacy in two Phase 3 trials but device needed some work so this was after the $13 high.
Currently a new protocol is being developed to run a non-placebo controlled trial for Zalviso, and this may start in January pending FDA go to protocol (details in CC).
Since 2014: Zalviso (15 mcg sufentanil with dispenser device) has been approved in EU, marketing partner paid approval milestone to ACRX of $15 million. Sept 2015
ACRX sold 75% of it's EU royalty stream to PDLI for $65 million (ACRX now has $100 million cash on hand). recent
1) During 2016 the new Phase 3 for Zalviso should commence to use to file US NDA re-submission.
2) ARX-04 pre-filing meeting with FDA to discuss NDA. ARX-04 is 30 mcg sufentanil single dose for application (battlefield and emergency room). 1st trial statistically significant completed 2015, 2nd phase 3 will be run soon in ER setting open label. NDA could be filed in 2016. Company mentions $1.3 billion peak sales in CC for ARX-04. To be submitted EU, also.
Summary: ACRX now has $100 million cash on hand. Zalviso approved in EU. Zalviso and ARX-04 trials in US should be run in 2016. NDA applications for Zalviso and ARX-04 to be submitted. EU submission of ARX-04.
ACRX may be in better shape now than 1 1/2 years ago regarding cash on hand and progress all together: EU partnership and approval of Zalviso gained, potential for approval of ARX-04 in US and EU pending final trial results (bigger market potential for ARX-04 than Zalviso according to management). Zalviso may finally gain US approval after requirements met.